Your proposal in few words
Foresee Biosystems designs and manufactures platforms for in-vitro electrophysiology based on a patented LASER technology that allows action potentials of cardiac cells to be recorded in an extremely non-invasive manner. This allows acute and chronic (up to 4 weeks) monitoring of cellular electrical activity. All these features make our products extremely advantageous in the evaluation of cardiotoxicity of drugs during pre-clinical testing, with the aim of reducing costs and development time for new drugs and significantly increasing safety.
What is your main purpose and the idea behind it?
The idea behind our activity stems from the long-standing work of two researchers at the IIT in Genoa: Francesco De Angelis and Michele Dipalo, who developed the LASER technology underlying the operation of our products. The entire work carried out has been supported by 2 European projects with a total budget of 1.55 M€ (ERC-CoG “Neuroplasmonics” and ERC-PoC “MAREP”) that have supported the technological development from 2014 to 2021. In 2018, Foresee Biosystems was awarded the “Best start-up project in Life Sciences” at SMARTCup Liguria, in Genoa. Our mission is to design a new generation of high-tech devices capable of accurately monitoring the acute and chronic cardiotoxicity of molecules and/or drugs on cardiac tissue during pre-clinical testing in drug evaluation processes.
How does the Startup Breeding experience help you in the growth and development of your business?
The Foresee Biosystems team is learning so much through this initiative because we have a mentor who is expert about the field we are entering. It’s a useful course because it highlights our weaknesses and allows us to address and consolidate them efficiently. Our coach is an extremely serious person who is able to pass on knowledge and concepts in a straightforward manner and this gives us an effective tool for understanding different areas beyond the R&D part.